# CaDAnCe-101 (NCT05006716)

> A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

No report yet. It can be ordered.

- Drugs tested: tacabrutideg (BGB-16673)
- Indication: B-cell malignancies

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05006716
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: BeOne Medicines
- Conditions: B-cell Malignancy; Marginal Zone Lymphoma; Follicular Lymphoma; Non-Hodgkin Lymphoma; Waldenström Macroglobulinemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Richter Transformation
- Interventions: Tacabrutideg
- Enrollment: 689
- Primary outcome: Phase 1: Number of Participants with Adverse Events (AEs)
- Primary outcome: Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Tacabrutideg
- Primary outcome: Phase 1: Recommended dose(s) for Expansion (RDFE) of tacabrutideg
- Primary outcome: Phase 2: Overall response rate (ORR)

## Indexed commentary on CaDAnCe-101 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 13
- X threads: 4
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=cadance-101-nct05006716

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05006716", "email": "<work email>"}; the inbox owner confirms by the emailed link.